Semax

Semax is a linear 7-residue peptide whose ACTH(4-10) core sequence (Met-Glu-His-Phe-Pro-Gly-Pro) provides the basis for its biochemical interaction profile, with the C-terminal Pro-Gly-Pro motif conferring resistance to peptidase cleavage relative to the parent ACTH fragment. The molecule's interaction profile in the literature spans BDNF and NGF expression modulation in cortical-tissue assays, melanocortin-related signaling intersection, and neuroplasticity-related pathway engagement in rodent-brain investigations. Pharmacokinetic descriptors documented in published animal-model studies include rapid absorption following intranasal paradigms and short systemic plasma residence under parenteral routes. All activity descriptors here are framed as documented in published research rather than as effects of the supplied product. Structural confirmation of supplied lots is established by mass spectrometry molecular-ion match to the C37H51N9O10S empirical formula, with HPLC-validated purity reported on each Certificate of Analysis.

Experimental domains documented in the published literature include BDNF and NGF gene-expression studies in cortical-tissue preparations, neuroplasticity-related pathway investigations, melanocortin-related signaling intersection assays, behavioral-neuroscience paradigms probing learning and memory in rodent models, structure-activity work comparing Semax against the parent ACTH(4-10) fragment, and neurotrophic-factor expression analysis in cell-culture systems. Investigators have also characterized the heptapeptide in studies of stress-response pathway intersection and in screening assays for nootropic-class neuropeptide research. Use in laboratory research extends to mechanism-elucidation paradigms where the molecule serves as a probe for ACTH-fragment-derived neuropeptide signaling. The reference standard is supplied for these and equivalent in-vitro and animal-model experimental contexts only, with no associated guidance for human, clinical, or veterinary application.

Each lot is characterized by reverse-phase HPLC for chromatographic purity and by mass spectrometry for molecular-ion confirmation against the C37H51N9O10S empirical formula. Purity is reported as an HPLC-area percentage on the Certificate of Analysis distributed with every lot, alongside the molecular-weight match within instrument tolerance. Peptide content where applicable is determined by amino-acid analysis or nitrogen-content assay following the analytical method specified on the COA. Residual solvent and water content are reported categorically when these parameters are part of the lot's release specification. The COA records the lot identifier, manufacturing date, and analytical method versions used, providing a traceable provenance chain from synthesis through release. Researchers requiring batch-level analytical detail should reference the COA distributed with the supplied material.

For laboratory storage, the lyophilized reference standard should be held at −20°C in its sealed, light-protected container until ready for analytical use. Allow vials to equilibrate to ambient temperature before opening to avoid moisture condensation on the lyophile. Reconstitution for in-vitro experimental use is typically performed in bacteriostatic water or a researcher-selected buffer compatible with the downstream assay; once reconstituted, store the working solution at 2–8°C and characterize stability in the relevant buffer prior to extended storage. Avoid repeated freeze-thaw cycles of reconstituted material — single-use aliquots are preferred for experiments where peptide integrity is assay-critical. These handling parameters reflect general best-practice for lyophilized peptide reference standards and do not constitute preparation guidance for human or veterinary application.